NASDAQ:SGMO

Sangamo Therapeutics SEC Filings & 10K Form

$11.94
+0.32 (+2.75 %)
(As of 06/24/2021 10:15 AM ET)
Add
Compare
Today's Range
$11.74
$11.98
50-Day Range
$10.17
$12.36
52-Week Range
$8.51
$19.43
Volume3,346 shs
Average Volume1.27 million shs
Market Capitalization$1.72 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.74

Sangamo Therapeutics (NASDAQ:SGMO) SEC Filings

DateFilerForm TypeView
06/14/2021
6:17 PM
Duraibabu Prathyusha (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/27/2021
4:28 PM
Sangamo Therapeutics (Filer)
Form 8-K/A
04/27/2021
7:49 PM
Fontenot Jason D. (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/27/2021
7:49 PM
Duraibabu Prathyusha (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/27/2021
7:46 PM
Duraibabu Prathyusha (Reporting)
Sangamo Therapeutics (Issuer)
Form 4/A
04/27/2021
7:45 PM
Duraibabu Prathyusha (Reporting)
Sangamo Therapeutics (Issuer)
Form 4/A
04/02/2021
3:12 PM
Sangamo Therapeutics (Filer)
Form DEF 14A
03/29/2021
6:11 PM
Duraibabu Prathyusha (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/25/2021
6:19 PM
LOEB GARY (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/19/2021
6:15 PM
Fontenot Jason D. (Reporting)
Sangamo Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
03/17/2021
4:06 PM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/01/2021
8:12 PM
Duraibabu Prathyusha (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/01/2021
8:11 PM
Ramelmeier Rolf Andrew (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/01/2021
8:10 PM
McClung David Mark (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/01/2021
8:09 PM
LOEB GARY (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/01/2021
8:08 PM
Macrae Sandy (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/01/2021
8:07 PM
Sangamo Therapeutics (Issuer)
Zakrzewski Joseph S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/01/2021
8:05 PM
Sangamo Therapeutics (Issuer)
Smith Karen L. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/01/2021
8:04 PM
Ramasastry Saira (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/01/2021
8:03 PM
PARKER H STEWART (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/01/2021
8:01 PM
Meyers James R (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/01/2021
7:59 PM
Markels John (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/01/2021
7:57 PM
Hillan Kenneth J. (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/01/2021
7:56 PM
Carey Robert (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2021
3:17 PM
Sangamo Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/16/2021
5:21 PM
Sangamo Therapeutics (Issuer)
Schott Robert J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/11/2021
1:09 PM
Sangamo Therapeutics (Subject)
WASATCH ADVISORS INC (Filed by)
Form SC 13G/A
02/10/2021
5:36 PM
Sangamo Therapeutics (Issuer)
Schott Robert J. (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
02/04/2021
10:42 AM
Sangamo Therapeutics (Subject)
WELLINGTON MANAGEMENT GROUP LLP (Filed by)
Form SC 13G/A
01/26/2021
7:24 PM
Macrae Sandy (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/14/2021
8:01 AM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/30/2020
6:51 PM
Ramelmeier Rolf Andrew (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2020
6:18 PM
Ramasastry Saira (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/15/2020
3:00 PM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/07/2020
6:32 AM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/30/2020
6:46 PM
Lee Sung (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/04/2020
3:23 PM
Sangamo Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/14/2020
6:46 PM
Sangamo Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
09/11/2020
8:11 PM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/11/2020
5:18 PM
Hillan Kenneth J. (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/11/2020
5:14 PM
Hillan Kenneth J. (Reporting)
Sangamo Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
08/05/2020
4:22 PM
Sangamo Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
08/05/2020
3:19 PM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/31/2020
7:16 PM
Boissel Stephane (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/30/2020
6:14 PM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/30/2020
6:02 PM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/29/2020
8:11 PM
McClung David Mark (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/24/2020
3:34 PM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/18/2020
1:58 PM
Sangamo Therapeutics (Filer)
Form 8-K/A
06/18/2020
8:26 AM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/05/2020
8:29 PM
Boissel Stephane (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2020
3:30 PM
Sangamo Therapeutics (Issuer)
Zakrzewski Joseph S (Reporting)
Form 4/A
05/22/2020
3:46 PM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/20/2020
4:22 PM
Sangamo Therapeutics (Issuer)
Zakrzewski Joseph S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2020
4:21 PM
Sangamo Therapeutics (Issuer)
Smith Karen L. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2020
4:19 PM
Ramasastry Saira (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2020
4:18 PM
PARKER H STEWART (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2020
4:17 PM
Meyers James R (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2020
4:14 PM
DILLY STEPHEN GEORGE (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2020
4:13 PM
Carey Robert (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2020
3:08 PM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/07/2020
5:05 PM
McClung David Mark (Reporting)
Sangamo Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
04/28/2020
5:59 PM
Duraibabu Prathyusha (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2020
3:50 PM
BIOGEN INC. (Reporting)
Biogen MA Inc. (Reporting)
Sangamo Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
04/17/2020
3:13 PM
BIOGEN INC. (Filed by)
Sangamo Therapeutics (Subject)
Form SC 13G
03/26/2020
6:18 PM
Duraibabu Prathyusha (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/23/2020
4:18 PM
Sangamo Therapeutics (Filer)
Form PRE 14A
03/19/2020
6:55 PM
PARKER H STEWART (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2020
8:09 PM
DILLY STEPHEN GEORGE (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2020
4:41 PM
Sangamo Therapeutics (Issuer)
Zakrzewski Joseph S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/28/2020
3:53 PM
Sangamo Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/28/2020
6:16 AM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/27/2020
10:54 AM
LOEB GARY (Reporting)
Sangamo Therapeutics (Issuer)
Form 4/A
02/27/2020
9:40 AM
Sangamo Therapeutics (Issuer)
Woolfson Adrian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2020
6:50 PM
Duraibabu Prathyusha (Reporting)
Sangamo Therapeutics (Issuer)
Form 4/A
02/26/2020
6:34 PM
Duraibabu Prathyusha (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2020
6:33 PM
Ramelmeier Rolf Andrew (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2020
6:32 PM
LOEB GARY (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2020
6:31 PM
Lee Sung (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2020
6:31 PM
Boissel Stephane (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2020
6:29 PM
Macrae Sandy (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2020
7:15 PM
Markels John (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2020
7:04 PM
Markels John (Reporting)
Sangamo Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
02/13/2020
2:24 PM
Sangamo Therapeutics (Subject)
STATE STREET CORP (Filed by)
Form SC 13G/A
02/12/2020
5:33 PM
Boissel Stephane (Reporting)
Sangamo Therapeutics (Issuer)
Form 5
Annual statement of changes in beneficial ownership of securities  
02/12/2020
10:01 AM
Sangamo Therapeutics (Subject)
VANGUARD GROUP INC (Filed by)
Form SC 13G/A
02/03/2020
4:52 PM
LOEB GARY (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/03/2020
8:16 AM
Sangamo Therapeutics (Filer)
Form CT ORDER
01/28/2020
6:11 PM
Macrae Sandy (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2019
7:03 AM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/26/2019
3:54 PM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/06/2019
3:33 PM
Sangamo Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/06/2019
3:25 PM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/05/2019
4:27 PM
Lee Sung (Reporting)
Sangamo Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
11/04/2019
3:16 PM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/26/2019
5:15 PM
Ramelmeier Rolf Andrew (Reporting)
Sangamo Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
08/14/2019
4:10 PM
Boissel Stephane (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/07/2019
3:44 PM
Sangamo Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/07/2019
3:37 PM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/18/2019
4:02 PM
Duraibabu Prathyusha (Reporting)
Sangamo Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
This page was last updated on 6/24/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.